The CELLVX-230 trial, a phase 2 study, is evaluating FK-PC101, a personalized immunotherapy, in patients with high-risk prostate cancer following radical prostatectomy.
Theragent and CellVax Therapeutics announced the first patient has been dosed in a Phase 2 clinical trial of FK-PC101, a personalized cancer immunotherapy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.